Pichi and associates are to be congratulated for their study on the intravitreal use of bevacizumab for the therapy of retinal macroaneurysms. In their multicenter trial on 38 eyes, Pichi and associates applied bevacizumab intravitreally 3 times and observed a complete regression of retinal edema and closure of the retinal macroaneurysms during the follow-up. The remarkable therapeutic success in Dr Pichi’s study agrees with a previous report on 2 patients, with the difference that these 2 patients received only one intravitreal injection of bevacizumab for the therapy of their retinal macroaneurysms. Since the investigation by Pichi and associates may become a landmark study on the treatment of retinal macroaneurysms, and since at least in some patients a single intravitreal injection of bevacizumab may be sufficient to achieve a complete closure of the retinal macroaneurysm, the question arises whether the conclusion of Dr Pichi’s study is that all patients with retinal macroaneurysms should receive a triple injection of bevacizumab in a standardized manner, or whether one may start with a single injection and observe.